Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada.
Diagn Microbiol Infect Dis. 2021 May;100(1):115324. doi: 10.1016/j.diagmicrobio.2021.115324. Epub 2021 Jan 23.
With surging global demand for SARS-CoV-2 testing capacity, laboratories seek automated, high-throughput molecular solutions, particularly for specimens not requiring specialized collection devices or viral transport media. Saliva specimens submitted from patients under investigation for COVID-19 from March to July 2020 were processed in the laboratory with sterile phosphate-buffered saline in a 1:2 dilution and tested using manual extraction and a commercial assay for detection of the SARS-CoV-2 E gene (LightMix®) in comparison to the Roche cobas® SARS-CoV-2 Test on the cobas® 6800 instrument. 34.4% (22/64) of saliva samples were positive for SARS-CoV-2. Positive and negative concordance between the LightMix® and cobas® assays were 100%. The overall invalid rate for saliva on the cobas® 6800 (1/128, 0.78%) was similar to the baseline invalid rate observed for nasopharyngeal swabs/viral transport media. Saliva is a feasible specimen type for SARS-CoV-2 testing on the cobas® 6800 platform, with potential to improve turnaround time and enhance testing capacity.
随着全球对 SARS-CoV-2 检测能力的需求不断增长，实验室正在寻求自动化、高通量的分子解决方案，特别是对于不需要特殊采集设备或病毒运输介质的标本。2020 年 3 月至 7 月期间，实验室用无菌磷酸盐缓冲盐水按 1:2 的比例对来自 COVID-19 待检患者的唾液标本进行处理，采用手动提取法和商业检测试剂盒（LightMix®）检测 SARS-CoV-2 E 基因（与 Roche cobas® SARS-CoV-2 Test 在 cobas® 6800 仪器上的检测结果进行比较）。结果显示，64 份唾液样本中有 34.4%（22/64）为 SARS-CoV-2 阳性。LightMix® 和 cobas® 检测方法的阳性和阴性符合率均为 100%。cobas® 6800 上唾液的总无效率（1/128，0.78%）与鼻咽拭子/病毒运输介质的基线无效率相似。唾液是 cobas® 6800 平台上 SARS-CoV-2 检测的一种可行标本类型，具有缩短检测周转时间和提高检测能力的潜力。
